Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.2501 | 0.6346 | 0.5 |
Schistosoma mansoni | tyrosine kinase | 0.1797 | 0.3299 | 0.32 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Loa Loa (eye worm) | TK/EGFR protein kinase | 0.3345 | 1 | 1 |
Echinococcus granulosus | epidermal growth factor receptor | 0.3345 | 1 | 1 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.2501 | 0.6346 | 0.5 |
Echinococcus multilocularis | insulin growth factor 1 receptor beta | 0.1069 | 0.0145 | 0.0145 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.2501 | 0.6346 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Schistosoma mansoni | tyrosine kinase | 0.1778 | 0.3217 | 0.3117 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.3345 | 1 | 1 |
Schistosoma mansoni | tyrosine kinase | 0.3345 | 1 | 1 |
Echinococcus multilocularis | epidermal growth factor receptor | 0.1797 | 0.3299 | 0.3299 |
Echinococcus multilocularis | insulin receptor | 0.1069 | 0.0145 | 0.0145 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.2501 | 0.6346 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.2501 | 0.6346 | 0.5 |
Echinococcus granulosus | epidermal growth factor receptor | 0.1797 | 0.3299 | 0.32 |
Echinococcus granulosus | melanoma receptor tyrosine protein kinase | 0.1797 | 0.3299 | 0.32 |
Chlamydia trachomatis | oxoacyl-ACP synthase III | 0.2501 | 0.6346 | 0.5 |
Schistosoma mansoni | tyrosine kinase | 0.1797 | 0.3299 | 0.32 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.